The structural considerations used in the design of OM-TMCD were aimed to enhance OM-TMCD anticonvulsant potency (compared to VPA) and to prevent VPA's two life-threatening side effects, i.e., induction of neural tube defects (NTDs) and hepatotoxicity.
After a few days, our preliminary results indicated that the rapid tests had a lower-than-expected sensitivity, and we changed our methodology to perform VPA's on all samples.
VPA's will also be more proactive, constantly discovering things that you might care about and even starting conversations with you about what they find.
VPA's were performed on cough aerosols collected from 20 subjects using the NIOSH sampler, 12 of whom were influenza-positive.
One of these cough aerosol VPA's was positive, with 0.8 pfu/ml per cough found in the first tube.
Initially, VPA's were performed only on nasopharyngeal swabs and cough aerosols from subjects with positive rapid influenza tests.
Several follow-up studies, however, failed to demonstrate any sustainable effect from VPA treatment - and it is possible that VPA's in vivo HDAC inhibition is too weak.
VPA's ability to inhibit histone deacetylase (HDAC) has been associated with autistic-like behavioural, anatomical and biochemical deficits in mice prenatally exposed to this drug [ 17], supporting the hypothesis that epigenetic mechanisms contribute to autism etiology.
